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Metalloporphyrins play important roles in areas ranging from 
biology to nanoscience. Using computational design, we converted 
metalloporphyrin specificity of cytochrome b562 from iron to 
fluorogenic zinc. The new variant had a near total preference for 
zinc representing a switch in specificity, which greatly enhanced the 
negligible aqueous fluorescence of free ZnPP in vitro and in vivo. 
Here, we describe how computational design can change the 
metalloporphyrin specificity of cytochrome b562 (cyt b562), a b-
type haem binding protein unit, from iron to fluorogenic and 
photochemically active zinc. Metalloporphyrins 1 represent an 
important class of organometallic compounds and play a major 
role in biology as essential cofactors to enable protein function 
in processes ranging from light harvesting to electron transfer 
to enzyme catalysis to O2 transport 2. Binding to a protein tunes 
and modulates the metalloporphyrin physiochemical 
properties. The metal centres used in biology are Fe (e.g. haem), 
Mg (e.g. chlorophyll) and, to a much lesser extent Co (Vitamin 
B12) and Ni (F430). This does not however represent the full 
metal repertoire available to porphyrins (e.g. Cu, Pt, Ag, Cd, Ir, 
Zn) 1. There is currently great interest in incorporating new 
metal cofactors into proteins. Such abiotic cofactors have 
recently been shown to confer new enzymatic catalytic routes 
3, 4. Zinc porphyrins such as zinc protoporphyrin IX (ZnPP, Figure 
1a) are one such class, playing important roles in clinical 
(including cancer therapy) and nanoscience settings. While 
ZnPP is not naturally utilised in biology as a protein cofactor, its 
aberrant presence in blood is commonly used to diagnose haem 
metabolism disorders 5. The photo-induced electron and energy 
transfer properties of zinc porphyrins make them particularly 
attractive for nanoscale applications, ranging from 
photosensitizers in solar cells to molecular optoelectronic 
components 6-9. ZnPP is inherently fluorescent but substantially 
quenched in aqueous solution 10, 11. Designer protein 
components have the potential to further enhance ZnPP use 
through: (i) activation of fluorogenic properties 12 in aqueous 
conditions as an aid to clinical sensing and cell imaging; (ii) 
providing an organised, defined and tunable self-assembling 
scaffold for nanodevice construction 6, 13-17. 
ZnPP incorporation within a protein scaffold has classically been 
achieved by either: (i) metal centre exchange (in the case of 
covalently attached porphyrins) that require harsh conditions 
unsuitable for most biological settings 13, 18, 19; (ii) facile 
exchange in the case of non-covalent porphyrin-protein 
complexes 11, 20. With regards to the latter, affinity for ZnPP is 
inherently low, with preference for the original haem cofactor; 
little attention is paid to optimising the protein interaction 
despite the structural and physicochemical variations on 
exchanging the porphyrin metal centre (Fig 1a). Here we show 
how computational design has been used to switch cyt b562 
specificity from its normal iron porphyrin (haem) to zinc. The 
new protein can activate ZnPP fluorescence both in vitro and in 
vivo.  
Figure 1. Porphyrin structure and cyt b562 variants. (a) Structure of haem (cyan) 
and ZnPP (green). The metalloporphyrin structure geometries were optimised 
using GAMESS-US 21. (b) Sequences of the cyt b562 variants and their corresponding 
nomenclature. The methionine that coordinates Fe in haem is highlighted with *. 
(c) Model of ZnPP-bound cyt b562ZnPP with the residues mutated that shift 
metalloporphyrin specificity highlighted. 
Cyt b562 (Figure S1) is a small, helical bundle protein that binds 
haem non-covalently 22-24. It is an important model for electron 
transfer 25-28, engineering novel components 29-34 and 
assembling supramolecular structures 6, 14, 35. ZnPP can replace 
haem through passive exchange 20, 33, 36 but the environment is 
non-ideal resulting in relatively low affinity binding (404 nM ±11 
KD; Table S1) and a significant background haem binding in vivo 
(vide infra). Factors include non-optimal metal coordination 
ligands and change in tetrapyrole structure and planarity due to 
the larger ionic radius of Zn2+(Fig 1a) 37, 38. 
Figure 2. Absorbance and fluorescence properties of cyt b562ZnPP binding variants. (a) ZnPP 
titration into 5 M cyt b562ZnPP (full line) or WT cyt b562 (dashed line). (b) absorbance 
spectra of free ZnPP (dashed red line), wt cyt b562 (blue line), and cyt b562ZnPP (black line). 
Inset is the Soret peak (top) and / bands (bottom). (c) fluorescence emission spectra 
(on excitation at 431 nm) of ZnPP in the presence (black line) and absence (red dashed 
line) of cyt b562ZnPP. 
The first stage in the design process was to optimise Zn 
coordination. Zn coordination is normally through soft ligands 
such as the cysteine thiol group and the imidazole group of 
histidine, or base ligands from the carboxylate groups of 
aspartate and glutamate; the native M7 S-methyl thioether 
group is not ideal. This was confirmed through computational 
analysis with cysteine considered the best, albeit still relatively 
poor, alternative (the M7C mutation; Figure S2). The second 
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native axial ligand, the imidazole group of H102, was considered 
optimal so was not changed (Figure S2). The M7C variant was 
generated and the measured ZnPP and haem affinity 
(dissociation constant, KD) were comparable (181 ±11 nM for 
ZnPP and 206 ±2 nM for haem; Table S1) so generating a starting 
mutant with slightly improved ZnPP binding and lower haem 
affinity. Replacement of Met7 with either His (a second 
potential coordinating ligand) or Gly lowered ZnPP binding 
affinity to that of wild-type cyt b562 with the bis-His mutant 
retaining specificity for haem (Table S2). The absorbance 
spectrum of cyt b562M7C (Fig S3) confirms ZnPP binding to the 
protein as indicated by the red shift in the Soret peak at 418nm 
for free ZnPP to a sharper peak at 431nm. The Soret and α/β 
band peaks of cyt b562M7C are slightly blue shifted (8-10 nm) 
compared to the ZnPP bound to wild-type cyt b562. The Soret 
peak is also broader for wt cyt b562 suggesting a mixed binding 
population compared to cyt b562M7C. The ZnPP α/β peaks ratio 
also switches on cyt b562 binding. 
To further optimise ZnPP binding, a more systematic in silico 
mutagenesis approach was adopted. Using the wt holo cyt b562 
crystal structure 39 as a starting point, every residue from 1 to 
20 was replaced to every possible residue and energy minimised 
to avoid clashes. The structures derived from the energy 
minimisation were used as the starting point for docking 
simulations using AutoDock 40 and Rosetta LigandDock 41. As a 
test for the accuracy, the in silico derived binding energy of wt 
cyt b562 was compared with the measured KD. The measured 
binding energy for wt cyt b562 (where ∆G=RT lnKD) is -8.7 kcal 
mol-1 for ZnPP, and -11.0 kcal mol-1 and for haem. These are 
close to the binding energies predicted from our modelling 
approach (Table S1). The in silico design process identified a 
variant with improved ZnPP binding energies termed cyt 
b562ZnPP. In addition to the M7C mutation, four other mutations 
were identified (L3K, E4D, T9C, L10R). The affinity of the variant 
for ZnPP was much lower (34 ±10 nM as an upper estimate 
based on fluorescence) compared to wt cyt b562 (Figure 2a; 
Table S1 and Figure S4) with minimal haem binding observed 
both in vivo (Figure 3a) and in vitro (Figure S4a). This represents 
a near total switch in specificity from haem to ZnPP. Mutation 
R10 arose in the later stages of the design and is buried in the 
holo form of the protein (Fig 1c) so it was surprising that not 
only was the L10R mutation tolerated but improved binding. 
Mutating residue 10 to either alanine or serine reduced affinity 
for ZnPP to >100 nM (Table S2). Analysis of the model suggests 
that the guanidinium group of R10 lies within 2-3 Å of the C7 
thiol group (Fig 1c and S5a); proton abstraction by R10 may 
generate a thiolate group, which is a better ligand for Zn binding 
than the C7 thiol. Lys3 may make an ionic bond to one of the 
carboxyl groups of ZnPP so stabilizing the complex (Supporting 
Figure S5b). The T9C mutation is difficult to rationalize but 
mutation to either alanine or serine reduced ZnPP affinity to 
~190 nM. The role of the E4D mutation is also unclear but it’s 
shortened side chain length may prevent steric and/or ionic  
clashes with puckered ZnPP while maintaining a negative charge 
at residue 4. Cyt b562ZnPP was analysed in more detail.  
Figure 3. ZnPP binding to cyt b562ZnPP. (a) Cell pellets of recombinantly expressed cyt 
b562ZnPP and the wild-type protein. (b) Rate of fluorescence emission increase 
(excitation 431 nm) of E. coli cell culture incubated with ZnPP with cells containing (black 
line) or without (red line) plasmid-based cyt b562ZnPP. Inset is the fluorescence emission 
spectra after 1 hr. (c) REES profile (emission wavelength, EX, versus excitation 
wavelength, EM) of free ZnPP (red line) and ZnPP-bound cyt b562ZnPP (black line). EX-
1 and EX-2 refer to the two separate emission peaks. (d) CD spectra of apo-cyt b562ZnPP 
(black dotted line) and cyt b562ZnPP bound to ZnPP (black line). 
Cyt b562ZnPP had a characteristic absorbance spectrum indicative 
of formation of ZnPP holo protein (Fig 2b), with an extinction 
coefficient of 158 mM cm-1 at 424 nm, 5 nm blue shifted 
compared to wt cyt b562. On binding cyt b562ZnPP, ZnPP 
fluorescence intensity increased >60 fold (Fig 2b). Excitation at 
431 nm gave the expected dual peak emission characteristic of 
ZnPP 19 (λEM 590 and 640 nm) with a Stoke’s shift of 160 nm and 
210 nm (Fig 2b). The peak ratio of the two emission peaks was 
circa 2:1 (590:640 nm). Protein-bound ZnPP could be excited at 
431 nm, 550nm and 590 nm (Fig S6). While the brightest 
emission originated from excitation at 431 nm the ability to 
excite at multiple and longer wavelengths has obvious benefits 
for biological imaging. These fluorescence characteristics were 
observed for wt cyt b562 and cyt b562M7C (Fig S7) suggesting that 
the mutations affected only binding affinity. The quantum yield 
for the combined emission peaks was measured to be ~92% 
generating a protein with a brightness of 146 mM-1cm-1, higher 
than many autofluorescent proteins 42-44. ZnPP fluorescence is 
quenched in aqueous solutions to the extent that the quantum 
yield could not be accurately measured. 
Coupled with the fluorogenic properties of ZnPP, cyt b562ZnPP 
could make a useful genetically encoded imaging agent. A 
prerequisite for cell imaging is that ZnPP should pass through 
membranes and have no significant fluorescence in the cell until 
it binds specifically to cyt b562ZnPP. E. coli cells expressing cyt 
b562ZnPP were colourless in comparison to those expressing wt 
cyt b562 (Figure 3a), which are a pink-red hue due to binding 
available haem with high affinity 31. This confirms the near-
absent affinity of cyt b562ZnPP for haem. On addition of ZnPP to E. 
coli cells expressing cyt b562ZnPP, fluorescence increased over 
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time until plateauing after ~40-50 min (Fig 3b). Cells with no 
plasmid-encoded cyt b562 exhibited low baseline fluorescence 
on addition of ZnPP, which remained steady over the course of 
the incubation. 
Red edge excitation shift (REES) analysis was performed to 
ascertain the effect of ZnPP binding to cyt b562ZnPP (Fig 3c). REES 
is an optical phenomenon where decreasing the excitation 
energy (increasing the excitation wavelength, 𝜆EX) gives rise to 
a red shift in the maximum of the fluorescence emission (𝜆EM). 
Such shifts can arise where the fluorophore exists in a range of 
discrete solvation environments that are sampled as part of an 
equilibrium of solvent-solute interaction energies 45. In some 
cases, decreasing the energy of excitation allows for photo-
selection of the discrete states that are red shifted (lower 
energy). We have recently demonstrated that for a single 
fluorophore (tryptophan) containing protein, the REES effect 
can inform on the equilibrium of conformational states 
accessible to the fluorophore 46. The REES data for free and 
protein-bound ZnPP are shown in Figure 3c and have been 
extracted for the α/β emission maximum shown in Figure 2b, 
𝜆EM-1 and 𝜆EM-2, respectively. Free ZnPP exhibits a significant 
REES effect that is reduced on binding to cyt b562ZnPP; the change 
in 𝜆EM-1 and 𝜆EM-2 respectively being 0.56 ± 0.02 nm-1 and 0.21 ± 
0.02 nm-1 for free ZnPP, which reduces to 0.12 ± 0.01 nm-1 and -
0.04 ± 0.03 nm-1 on binding cyt b562ZnPP. These data therefore 
suggest that the free ZnPP exists in an equilibrium of discrete 
solvation states and that this equilibrium collapses to essentially 
a single state on binding to the protein. These data therefore 
suggest tight ZnPP binding within the core of the protein, with 
limited solvent access, akin to haem binding. To further confirm 
ZnPP binding to cyt b562ZnPP, CD spectroscopy was used to 
monitor the expected transition from a partially folded helical 
structure to a folded 4-helix bundle on co-factor binding. On 
addition of ZnPP to cyt b562ZnPP, the deepening of troughs at 
~208 nm and 222 nm was observed confirming the increase in 
helical character, with the spectra of holo-cyt b562ZnPP similar to 
that observed for wt holo-cyt b562 (Fig 3d).  
Using systematic computationally guided engineering, the 
metalloporphyrin specificity of cyt b562 can be switched to ZnPP; 
the affinity is on a par with the natural haem cofactor and 
represented a near total switch in specificity. More generally, it 
provides a route for improving affinity of various different 
haemoproteins for ZnPP and other metalloporphyrins, in which 
the haem can be replaced by the photosensitizer effect of ZnPP 
13, 47 or the catalytic properties of Ir and Cu porphyrins 3, 4. The 
design process has shown changing metal coordinating ligands 
is not the defining step but that optimising residues adjacent to 
the metal coordination site is critical. 
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